Survival analysis of local excision vs total mesorectal excision for middle and low rectal cancer in pT1/pT2 stage and intermediate pathological risk

Table 1 Patient characteristics

Variable	TME (N = 134) number (%)	LE (N = 39) number (%)	P value
Age (y/o)	63.0 ± 12.9	59.7 ± 13.9	0.178
BMI (kg/m2)	24.3 ± 3.5	25.3 ± 4.4	0.226
Sex			1.000
Male	68 (50.7)	20 (51.3)
Female	66 (49.3)	19 (48.7)
Family cancer history	43 (32.1)	16 (41.0)	0.339
CEA (ng/mL)	2.88 ± 3.5	2.14 ± 1.1	0.757
Albumin < 3.5 (g/dL)	8 (6.0)	1 (2.9)	0.688
Hemoglobin < 10 (g/dL)	7 (5.2)	1 (2.6)	0.685
Ostomy			< 0.001
No	69 (51.5)	36 (92.3)
Temporary	50 (37.3)	1 (2.6)
Permanent	15 (11.2)	2 (5.1)
Adjuvant therapy	21 (15.7)	17 (43.6)	< 0.001
Chemotherapy	*21 (15.7)	**1 (2.6)
CCRT	0 (0)	**16 (41.0)
Post-op morbidity	38 (28.4)	2 (5.1)	0.002
Early	25 (18.7)	2 (5.1)	0.045
Late	22 (16.4)	0 (0)	0.005

TME total mesorectal excision, LE local excision, BMI body mass index, CEA carcinoembryonic antigen, CCRT concurrent chemoradiation
*Including tegafur and uracil in 17 patients, intravenous form 5-FU and leucovorin in 3 patients, and oxaliplatin plus intravenous 5-Fu/LV (FOLFOX) for 6 months in 1 patient
**Including tegafur and uracil in 1 patient, tegafur, and uracil with long-course radiotherapy in 14 patients, and 5-FU/LV with long-course radiotherapy in 2 patients

ISSN: 1477-7819